Regarding Atropine : A July 2023 report from NIH (the US government's biomedical and public health research body) is titled "Low-dose atropine eyedrops no bett

Regarding Atropine : A July 2023 report from NIH (the US government's biomedical and public health research body) is titled "Low-dose atropine eyedrops no better than placebo for slowing myopia progression". https://www.nih.gov/news-events/news-releases/low-dose-atropine-eyedrops-no-better-placebo-slowing-myopia-progression https://www.nih.gov/news-events/news-releases/low-dose-atrop... It infers a possible significant racial or genetic divide in the effectiveness of the atropine treatment, also given that some other atropine studies, which show success, tend (as far as I've seen) to involve Asian demographics. In any case, I am a total layperson, only here to note that fairly authoritative sources (e.g. in this case, a co-author being a professor of ophthalmology at Johns Hopkins University) appear to still be at odds about the application and demographic effectiveness of the atropine treatment, about which several general claims are made elsewhere in these HN comments.